

- Private biopharmaceutical company with presence in France and UK
- Expert antibacterial discovery team backed by the Wellcome Trust
- Strong expertise in bacterial metalloenzyme inhibition (e.g. NDM-1)
- First-in-class programs addressing the highest unmet needs



**Nosocomial infections
by carbapenem-resistant *Enterobacteriaceae* (CRE)**

- Most urgent bacterial threat,
- 9,000+ CRE infections per year (US)
- High mortality rates



**Chronic *Pseudomonas* infections in
Cystic Fibrosis (CF) patients**


- CF most common fatal genetic disease among Caucasians
 - 30,000 CF sufferers (US)
 - No cure

Fast moving programs on their way to the clinic

Supported by
wellcometrust

2

Metallo- β -lactamase inhibitors (MBLi)




- **To be combined with a carbapenem (IV)**
- **Advanced in vivo lead series**
 - Broad spectrum inhibition of clinically-relevant MBLs (NDM, VIM)
 - Good solubility and stability
 - Excellent PK compatible with partner carbapenem
 - Robust *in vivo* efficacy in relevant mouse model



PC declaration scheduled Q1 2017

Pseudomonas Elastase inhibitors (PEi)




- **Adjuvant to SOC for treatment of chronic PA infections (inhaled)**
- **In vitro lead series identified**
 - Targeting the *Pseudomonas* elastase, essential virulence factor in chronic and acute disease
 - Inhibiting LasB production and tobramycin persistence in PA cultures
 - Good potency, selectivity, and whole cell activity
 - Excellent solubility and lung PK



PC declaration scheduled Q1 2018

Raising €15M to significant value inflexion point in 2019



- Ongoing Series A: €15M in installment payments aligned with tangible milestones
- Opportunity for significant supplemental non-dilutive funding (IMI, BARDA,...)
- Partering opportunities available leveraging our metalloenzyme inhibition expertise
- >€25M Series B (or IPO) in 2019 will fund subsequent clinical development